13,157 results on '"Genentech Inc."'
Search Results
102. New Drug Development Findings Has Been Reported by Investigators at Genentech Inc. (Clinical Pharmacology Applications of Real-world Data and Real-world Evidence In Drug Development and Approval-an Industry Perspective)
103. Genentech announces FDA acceptance of BLA for crovalimab to treat PNH
104. Genentech's Alecensa shows promise in Phase III study for early-stage ALK-positive lung cancer
105. SAN DIEGO RISING: North County Construction Includes Maste Planned Communities, Medical Facilities
106. Study Results from Genentech Inc. Update Understanding of Biotechnology (A Comparative Clinical Pharmacology Analysis of Fda-approved Targeted Covalent Inhibitors Vs. Reversible Inhibitors In Oncology)
107. Research Data from Genentech Inc. Update Understanding of Biotechnology (Identification of Infectious Viruses for Risk-based Virus Testing of Cho Unprocessed Bulk Using Next-generation Sequencing)
108. Recent Findings in Monoclonal Antibodies Described by Researchers from Genentech Inc. (Immunogenicity of Atezolizumab: Influence of Testing Method and Sampling Frequency On Reported Anti-drug Antibody Incidence Rates)
109. Reports Summarize Biotechnology Study Results from Genentech Inc. (Context-specific Stress Causes Compartmentalized Sarm1 Activation and Local Degeneration In Cortical Neurons)
110. Studies from Genentech Inc. Yield New Information about Non-Small Cell Lung Cancer (Cost-effectiveness of Large-panel Next-generation Sequencing In Guiding First-line Treatment Decisions for Patients With Nonsquamous Advanced Non-small Cell ...)
111. Data from Genentech Inc. Advance Knowledge in Personalized Medicine (Accelerated Drug-resistant Variant Discovery With an Enhanced, Scalable Mutagenic Base Editor Platform)
112. Emory University Researcher Illuminates Research in Non-Small Cell Lung Cancer (ALK testing patterns in early-stage non-small cell lung cancer: A real-world evidence study)
113. Studies from Genentech Inc. Reveal New Findings on Geographic Atrophy (Intraocular Pressure Outcomes After Lampalizumab Injections In Patients With Geographic Atrophy)
114. Data on Biotechnology Discussed by Researchers at Genentech Inc. (An Integrated Hepatocyte Stability Assay for Simultaneous Metabolic Stability Assessment and Metabolite Profilings)
115. FDA Approves Genentech's Vabysmo Prefilled Syringe PFS for Three Leading Causes of Vision Loss
116. New Data from Genentech Inc. Illuminate Findings in Liver Cancer (Imbrave152/skyscraper-14: a Phase Iii Study of Atezolizumab, Bevacizumab and Tiragolumab In Advanced Hepatocellular Carcinoma)
117. Genentech gains FDA approval for Vabysmo prefilled syringe in treating causes of vision loss
118. Genentech gains FDA approval for Vabysmo prefilled syringe in treating causes of vision loss
119. Genentech Inc. Researcher Highlights Research in Biomarkers (Diffusion Tensor MRI is sensitive to fibrotic injury in a mouse model of oxalate induced chronic kidney disease)
120. Genentech ends trial as combination therapy fails to meet efficacy endpoints in lung cancer
121. Genentech ends trial as combination therapy fails to meet efficacy endpoints in lung cancer
122. Data on Biotechnology Discussed by Researchers at Genentech Inc. (Optimization of a Novel Del Hit That Binds In the Cbl-b Sh2 Domain and Blocks Substrate Binding)
123. Research Conducted at Genentech Inc. Has Provided New Information about Pulmonary Fibrosis [Pursuing Clinical Predictors and Biomarkers for Progression In Ild: Analysis of the Pulmonary Fibrosis Foundation (Pff) Registry]
124. Researchers from Genentech Inc. Provide Details of New Studies and Findings in the Area of Biotechnology [Speed-mode Cell Line Development (Cld): Reducing Chinese Hamster Ovary (Cho) Cld Timelines Via Earlier Suspension Adaptation and Maximizing ...]
125. New Science Research from Genentech Inc. Outlined (Cystine-knot peptide inhibitors of HTRA1 bind to a cryptic pocket within the active site region)
126. New Food Allergies Study Findings Have Been Reported by Researchers at University of Southern Florida [Open the Mental Health Burden of Food Allergies: Insights From Patients and Their Caregivers From the Food Allergy Research & Education (Fare) ...]
127. Researchers Submit Patent Application, 'Methods Of Making Fucosylated And Afucosylated Forms Of A Protein', for Approval (USPTO 20240158536)
128. 'FC Variants and Methods for Their Production' in Patent Application Approval Process (USPTO 20240158513)
129. FDA Grants Priority Review to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
130. FDA Grants Breakthrough Therapy Designation to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
131. Immunome Welcomes Kinney Horn as Chief Business Officer
132. Immunome Appoints Kinney Horn as Chief Business Officer
133. Shape Therapeutics Announces Appointment of Matt Valentino as Chief People Officer
134. 8-K: 89bio, Inc
135. FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
136. Genentech's Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
137. Genentech's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
138. 424B3: KAZIA THERAPEUTICS LTD
139. 10-K: KINETA, INC./DE
140. 10-K: ADAPTIMMUNE THERAPEUTICS PLC
141. Patent Issued for Adjuvant treatment of HER2-positive breast cancer (USPTO 12128103).
142. Patent Issued for Deep convolutional neural networks for tumor segmentation with positron emission tomography (USPTO 12115015).
143. Patent Issued for Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof (USPTO 12110341).
144. "Sulfonimidamde Compounds And Uses Thereof" in Patent Application Approval Process (USPTO 20240336625).
145. Researchers Submit Patent Application, "Stable Anti-Cd79b Immunoconjugate Formulations", for Approval (USPTO 20240325559).
146. "Tie2-Binding Agents And Methods Of Use" in Patent Application Approval Process (USPTO 20240327528).
147. Researchers Submit Patent Application, "Methods For Viral Inactivation And Other Adventitious Agents", for Approval (USPTO 20240309314).
148. Researchers Submit Patent Application, "Amides As Cbl-B Inhibitors", for Approval (USPTO 20240300927).
149. Patent Issued for Diagnostic and therapeutic methods for cancer (USPTO 12078638).
150. Patent Issued for Phenoxy-pyridyl-pyrimidine compounds and methods of use (USPTO 12071425).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.